SAN ANTONIO – StemBioSys Inc. announced today that it has entered into an agreement with SeouLin Bioscience to distribute and market StemBioSys products in The Republic of Korea (South Korea).
Initially, the agreement will cover StemBioSys’ cell expansion product BM-HPME®, but as additional products are added to StemBioSys’ portfolio in the future, these products will also be included in the distribution agreement, according to StemBioSys President & CEO Bob Hutchens.
“We have seen the importance of South Korea in the broader area of regenerative medicine and are delighted that we have been able to establish a partnership with SeouLin Bioscience,” he said.
EulMoon Hwang, CEO of SeouLin Bioscience, said, “We are very pleased to have the opportunity to work with StemBioSys and to bring its innovative product to the Korean market.”
Hutchens noted that the SeouLin distribution agreement is the second of its kind for StemBioSys. In late May, StemBioSys announced an agreement with Funakoshi Co. LTD of Japan as its first distributor.
“Given the important role that specialized distributors play in the sales and marketing of life science tools such as our BM-HPME®, we look forward to announcing more distribution agreements in other key markets around the world in the months ahead,” he said.
About SeouLin Bioscience Co., Ltd.
SeouLin Bioscience Co., Ltd. has been successfully serving Korean customers for 34 years in bio industry. SLB sets a high value on “Leading Total Solutions in Life Sciences” by human-centered mind management and is a leading distributor of life science reagents and scientific equipment in Korea.